Natco Pharma Limited
NSE: NATCOPHARMINE987B01026·HealthcareSmallcap 250·www.natcopharma.co.in ↗·Mcap ₹15,007 Cr·Listed 1995
₹839.30▼ ₹2.70  (−0.32%)
52W: ₹789 – ₹1,227 · Vol: 3.7L shares · Close 25 Sept
Set Alert

News & Filings

NSE filings · newest first · 5 on record

Yesterday

Newspaper Publication of Record date for Rights Issue
Newspaper noticeCopy of Newspaper Publication16:13 IST PDF 5.78 MB XBRL

Fri, 25 Sept, 2026

Record date for the purpose of Rights is 01-Oct-2026.
Record dateRecord Date11:23 IST PDF 182.54 KB XBRL
Issue of Securities on Rights Basis
Fund raiseIssue of Securities11:21 IST PDF 255.38 KB XBRL
Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : 21, i.e 2 Equity Shares for every 21 Equity Shares held at an Issue Price of Rs. 750 per share (including a premium of ₹ 748/- (Rupees Seven Hundred and Forty Eight only) per Rights Equity Share)
Fund raiseRights Issue11:17 IST PDF 255.38 KB XBRL

Mon, 21 Sept, 2026

'Intimation regarding receipt of In-Principle Approval for the Rights Issue '.
General updateUpdates22:48 IST PDF 2.76 MB XBRL
Source: NSE corporate announcements, as filed by the company. Times are IST. Press coverage is not included yet.
Filing activity · 30 days
5filings · +5 vs the 30 days before
● Corporate actions 3● Other 2
NSE filings by type. Press coverage and sentiment are not included yet.
Material vs routine · 90 days
Material events 3 in 90 days
25 SeptRecord date Record date for the purpose of Rights is 01-Oct-2026. PDF
25 SeptFund raise Issue of Securities on Rights Basis PDF
25 SeptFund raise Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : 21, i.e 2 Equity Shares for every 21 Equity Shares held at an Issue Price of Rs. 750 per share (including a premium of ₹ 748/- (Rupees Seven Hundred and Forty Eight only) per Rights Equity Share) PDF
Routine disclosures 2
other 2
Split by NSE filing category: business events (results, ratings, deals, leadership, capital actions, regulatory) versus schedules, notices and general updates. Not a view on importance.
Corporate Actions
loading…